Combination of targeted therapy and immunotherapy in melanoma. - Wikidata - awgldk - TriplyDB

Combination of targeted therapy and immunotherapy in melanoma.

Combination of targeted therapy and immunotherapy in melanoma.

http://www.wikidata.org/entity/Q37918893

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Optimal management of metastatic melanoma: current strategies and future directions Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma Predicting positive margins in resection of cutaneous melanoma of the head and neck.High drug-loading nanomedicines: progress, current status, and prospects.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.Immunotherapy in nonmelanoma skin cancer.Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy.Tissue transglutaminase activity protects from cutaneous melanoma metastatic dissemination: an in vivo study.Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.

P2860

Q21131200-AFF376CD-FD03-4C2C-A712-8EF3D94C0C81 Q26997338-200B254F-7C72-4006-84EF-3AA2574577FB Q27851927-BCFFD717-0BEE-4CEA-84B4-5F3B5DDDB370 Q30416873-730AFB3C-3D4C-4191-91DD-140C51149B1F Q30456466-AC63DB40-BE5D-4537-BAAD-91CA859CE219 Q33766568-8A548F1D-D1E8-4822-A0D9-AD662EB1934B Q33931434-298097B6-2ABD-4A7D-B14A-89EA41A65E33 Q34361976-850D5FFE-A6E6-4B0B-9024-D52610F723E9 Q36194822-E1FBB00E-104A-442B-8780-17AB505B86E7 Q36206219-726C44D6-4AAF-44F6-8961-43F2A7C637D0 Q36643680-AF52C462-2597-4E22-960D-E6261551D803 Q37065888-BC9A4AE4-8634-44F3-AEBA-26223E282B01 Q37360534-63CD3E5A-6705-46C1-A35A-E6E4615B0DCA Q37392729-8ECA6643-E6F0-4022-A369-25604ED966CF Q37534973-F213EA53-EB0C-4CFF-B02F-2C310B10E1D8 Q37946449-BEAD968E-53B8-4DEC-ADA7-87BDE6FBBE6E Q38014084-DD62B8DA-BEE8-4302-82F7-1D47CB72FFA0 Q38998443-B76CAED6-F80E-4127-AB8B-691CA19177F7 Q39161026-1C8A5116-D67E-4E17-BBDF-85B789694AE9 Q39316877-8D0BDB3A-458C-4D5B-BBCF-4BD01EC82AF6 Q39445924-85C311A3-EB25-486A-A973-29E97DD266C0 Q41830617-800C561A-6AC7-40A3-A134-3716D7E100F4 Q50425077-8C1E183F-BBE2-4FB8-9C96-2776F2ECAA50

P2860

Combination of targeted therapy and immunotherapy in melanoma.

http://www.wikidata.org/entity/Q37918893

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Combination of targeted therapy and immunotherapy in melanoma.

@en

Combination of targeted therapy and immunotherapy in melanoma.

@nl

type

label

Combination of targeted therapy and immunotherapy in melanoma.

@en

Combination of targeted therapy and immunotherapy in melanoma.

@nl

prefLabel

Combination of targeted therapy and immunotherapy in melanoma.

@en

Combination of targeted therapy and immunotherapy in melanoma.

@nl

P1433

Q37918893-B4109199-AED5-4372-B29E-AFDE28ED7216

P1476

Q37918893-2A2E1B40-F48E-4ED1-88C6-9B6D69CF3A42

P2093

Q37918893-3391C32A-37FA-407C-B8F2-6F86F9DDB0DA

Q37918893-96690673-BE4E-4116-9782-C587A1EB6C04

Q37918893-E09E0EFE-7084-4FB1-A50C-8F6051804E05

Q37918893-FC4D6A43-91E8-41DF-9105-AE7448B9B4D1

P2860

Q37918893-02CCBB40-81BE-4C48-B09C-16E1D40FABDE

Q37918893-0425393C-E4F6-4ED2-BFFB-663B628C8F8C

Q37918893-05A518BF-117A-4347-ACA4-61D88EC36725

Q37918893-060D600F-B870-4FFB-AF05-151ECC9FAED6

Q37918893-08C12123-1512-45A6-9111-279E75296A13

Q37918893-092C5576-832A-458D-A1F6-EAA5B3CF2F81

Q37918893-101920E2-FF01-4697-97E3-8D554DEA356B

Q37918893-1AD7FF74-DD6D-4AE3-9E2B-63EBB1E3938F

Q37918893-1E76B5F6-6FC1-40FC-BD6E-5B156B9D1311

Q37918893-2AC1778B-C5BA-46EF-8027-D7A00E5B1C41

P2888

Q37918893-29E62EE2-682E-4D96-8503-942AC9871432

P304

Q37918893-8CBFD4FB-1FC6-4221-8A74-FFC6FD336CC3

P31

Q37918893-1527EFBE-36C9-484B-B635-FC5FE52EF24A

P356

Q37918893-13BCF3F9-C6E4-435C-AE5E-73E5BA5D7148

P433

Q37918893-131501A1-5596-47A3-8C8B-A0F35D3A972D

P478

Q37918893-A48173B9-FA37-4889-81F7-C98C9FEBD1D0

P577

Q37918893-E5556A28-A155-4E2A-9486-3B10AEA23F64

P698

Q37918893-469331D1-32E3-4F5F-B4F9-E2D72E716481

P921

Q37918893-0E6CFB90-89A0-4AE3-A2DF-FEAB6EB1DD5C

P356

S00262-011-1079-2

P1433

Cancer Immunology, Immunotherapy

P1476

Combination of targeted therapy and immunotherapy in melanoma.

@en

P2093

Anna I Hooijkaas

http://www.w3.org/2001/XMLSchema#string

Christian U Blank

http://www.w3.org/2001/XMLSchema#string

John B Haanen

http://www.w3.org/2001/XMLSchema#string

Ton N Schumacher

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

T cell activation

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

P2888

s00262-011-1079-2

P304

1359-1371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1079-2

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21847631

http://www.w3.org/2001/XMLSchema#string

P921